CN Patent

CN107176954B — 一种egfr抑制剂的药用盐及其晶型、制备方法和应用

Assigned to Wuxi Shuangliang Biological Technology Co Ltd · Expires 2019-01-11 · 7y expired

What this patent protects

本发明提供一种EGFR抑制剂的药用盐及其晶型、制备方法和应用。所述EGFR抑制剂的结构式如式I所示，所述药用盐为所述EGFR抑制剂的甲磺酸盐、对甲苯磺酸盐、磷酸盐、盐酸盐或柠檬酸盐。本发明的EGFR抑制剂的药用盐具有特定的晶型，比相应的游离碱的溶解性和稳定性更高，更适合于制备治疗癌症(特别是非小细胞肺癌)的药物，满足生物利用度和药效要求。

USPTO Abstract

本发明提供一种EGFR抑制剂的药用盐及其晶型、制备方法和应用。所述EGFR抑制剂的结构式如式I所示，所述药用盐为所述EGFR抑制剂的甲磺酸盐、对甲苯磺酸盐、磷酸盐、盐酸盐或柠檬酸盐。本发明的EGFR抑制剂的药用盐具有特定的晶型，比相应的游离碱的溶解性和稳定性更高，更适合于制备治疗癌症(特别是非小细胞肺癌)的药物，满足生物利用度和药效要求。

Drugs covered by this patent

Patent Metadata

Patent number
CN107176954B
Jurisdiction
CN
Classification
—
Expires
2019-01-11
Drug substance claim
No
Drug product claim
No
Assignee
Wuxi Shuangliang Biological Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.